Siemens Healthineers Intends to Close Fast Track Diagnostics

• Shift follows a periodic strategic review of portfolio contributions and market opportunity 
• Demand for Fast Track Diagnostic testing portfolio declined significantly from peak of pandemic 
• Diagnostics business to focus on centralized laboratory testing, specialty testing, point of care

Siemens Healthineers announced today it intends to close its Fast Track Diagnostics unit, a small collection of polymerase chain reaction (PCR) testing products that is part of the Diagnostics business. This portfolio is primarily sold in Europe. Demand for the Fast Track Diagnostics portfolio has fallen significantly since the peak of the COVID-19 pandemic. Fast Track Diagnostics is a minor player in the molecular diagnostics space and represents a very small part of the overall revenue of the Siemens Healthineers Diagnostics business. 

About 90 employees, mostly based in Luxembourg, are affected. Conversations with local employee representatives are under way, and local labor regulations and guidelines will be followed in accordance with standard company practice. Siemens Healthineers intends to close the Fast Track Diagnostics unit by September 2024. 

Siemens Healthineers offers in vitro diagnostic test solutions for nearly every clinical environment. Its central laboratory analyzers are used in research laboratories, clinical laboratories of local community hospitals, independent specialty laboratories, and in the largest reference labs in the world. Point-of-care testing solutions support care everywhere from remote pop-up health clinics to community physician offices, and outpatient care facilities to patients’ bedsides in hospital units. Siemens Healthineers has differentiated its in vitro diagnostic test offerings with flexible, scalable, and integrated automation capabilities that increase control over laboratory testing and operational workflows.